A hantavirus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates

Current Gene Therapy

Volumn 14, Issue 3, 2014, Pages 200-210

  Kwilas, Steve ^a   Kishimori, Jennifer M ^a   Josleyn, Matthew ^a   Jerke, Kurt ^a   Ballantyne, John ^b   Royals, Michael ^c   Hooper, Jay W ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Aldevron LLC   (United States)

^c Cedar Industries   (United States)

Author keywords

DNA vaccine; Hantavirus; Jet injection

Indexed keywords

ANDES VIRUS DNA VACCINE; DNA VACCINE; HANTAVIRUS PULMONARY SYNDROME DNA VACCINE; NEUTRALIZING ANTIBODY; PLASMID DNA; SIN NOMBRE VIRUS DNA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; DNA IMMUNIZATION; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HANTAVIRUS PULMONARY SYNDROME; IMMUNOGENICITY; JET INJECTION; JET INJECTOR; NONHUMAN; RABBIT; RHESUS MONKEY; SEROCONVERSION; SIN NOMBRE VIRUS; VIRUS NEUTRALIZATION; VIRUS TITRATION; ANIMAL; BLOOD; DEVICES; ELECTROPORATION; FEMALE; HANTAVIRUS; HANTAVIRUS INFECTIONS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; PRIMATE; SERODIAGNOSIS; VACCINATION;

ANDES VIRUS; ANIMALIA; HANTAVIRUS; ORYCTOLAGUS CUNICULUS; PRIMATES; SIN NOMBRE VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ELECTROPORATION; FEMALE; HANTAVIRUS; HANTAVIRUS INFECTIONS; HANTAVIRUS PULMONARY SYNDROME; INJECTIONS, INTRAMUSCULAR; NEUTRALIZATION TESTS; PRIMATES; RABBITS; SIN NOMBRE VIRUS; VACCINATION; VACCINES, DNA;

EID: 84906895913     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/1566523214666140522122633     Document Type: Article

References (33)

1. Knust B, PE Rollin. Twenty-year summary of surveillance for human hantavirus infections, United States. Emerg Infect Dis 2013; 19(12): 1934-7.
2. Figueiredo LT, Souza WM, Ferrés M, Enria DA. Hantaviruses and cardiopulmonary syndrome in South America. Virus Res 2014; doi: 10.1016/j.virusres.2014.01.015. [Epub ahead of print].
3. Hammerbeck CD, Hooper JW. Hantavirus Vaccines, in New Generation Vaccines, M.M. Levine, Editor. 2010, informa healthcare: New York. p. 905-13.
4. Arikawa J, Yao JS, Yoshimatsu K, Takashima I, Hashimoto N. Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies. Arch Virol 1992; 126(1-4): 271-81.
5. Brocato R, Josleyn M, Ballantyne J, Vial P, Hooper JW. DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS). PLoS One 2012; 7(4): e35996.
6. Custer DM, Thompson E, Schmaljohn CS, Ksiazek TG, Hooper JW. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J Virol 2003; 77(18): 9894-905.
7. Hooper JW, Josleyn M, Ballantyne J, Brocato R. A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate panhantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS). Vaccine 2013; 31(40): 4314-21.
8. Brocato RL, Josleyn MJ, Wahl-Jensen V, Schmaljohn CS, Hooper JW. Construction and nonclinical testing of a puumala virus synthetic m gene-based DNA vaccine. Clin Vaccine Immunol 2013; 20(2): 218-26.
9. Hooper JW, Custer DM, Thompson E, Schmaljohn CS. DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys. J Virol 2001; 75(18): 8469-77.
10. Hooper JW, Kamrud KI, Elgh F, Custer D, Schmaljohn CS. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection. Virology 1999 255(2): 269-78.
11. Weniger BG, Papania MJ. Alternative vaccine delivery methods. Molecules 2008; 25: 26.
12. Nelson EA, Lam HS, Choi KC, et al. A pilot randomized study to assess immunogenicity, reactogenicity, safety and tolerability of two human papillomavirus vaccines administered intramuscularly and intradermally to females aged 18-26 years. Vaccine 2013; 31(34): 3452-60.
13. Petrovsky N, Honda-Okubo Y, Royals M, Bragg K, Sajkov D. A randomized controlled study to assess the immunogenicity and tolerability of a 2012 trivalent seasonal inactivated influenza vaccine administered via a disposable syringe jet injector device versus a traditional pre-filled syringe and needle. Trial Vaccinol 2013; 2(0): 39-44.
14. Ploemen IH, Hirschberg HJ, Kraan H, et al. Minipigs as an animal model for dermal vaccine delivery. Comp Med 2014; 64(1): 50-4.
15. Soonawala, D, Verdijk P, Wijmenga-Mansuur AJ, et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine 2013; 31(36): p. 3688-94.
16. Soonawala D, Verdijk P, Wijmenga-Monsuur AJ, et al. Isolation and initial characterization of a newfound hantavirus from California. Virology 1995; 206(2): 963-72.
17. Hooper JW, Larsen T, Custer DM, Schmaljohn CS. A lethal disease model for hantavirus pulmonary syndrome. Virology 2001; 289(1): 6-14.
18. Ray N, Whidby J, Stewart S, Hooper JW, Bertolotti-Ciarlet A. Study of Andes virus entry and neutralization using a pseudovirion system. J Virol Methods 2010; 163(2): 416-23.
19. Higa MM, Petersen J, Hooper J, Doms RW. Efficient production of Hantaan and Puumala pseudovirions for viral tropism and neutralization studies. Virology 2012; 423(2): 134-42.
20. Wahl-Jensen V, Chapman J, Asher L. Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamsters. J Virol 2007; 81(14): 7449-62.
21. Boudreau EF, Josleyn M, Ullman D, et al. A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome. Vaccine 2012; 30(11): 1951-8.
22. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical Applications of DNA Vaccines: Current Progress. Clin Infect Dis 2011; 53(3): 296-302.
23. Hooper JW, Moon JE, Paolino KM, et al. A Phase 1 clinical trial of Hantaan virus and Puumala virus M segment DNA vaccines for hemorrhagic fever with renal syndrome delivered by intramuscular electroporation. Clini Microbiol Infect 2014; doi: 10.1111/1469-0691.12553.
24. Astellas Pharma Global Development, Inc. A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV) - Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) (HELIOS). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2014 Mar 07]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01877655 NLM Identifier: NCT01877655.25
25. Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol 2013; 4:354.
26. Rao SS, Gomez P, Mascola JR, et al. Comparative evaluation of three different intramuscular delivery methods for DNA immunization in a nonhuman primate animal model. Vaccine 2006; 24(3): 367-73.
27. Aguiar JC, Hedstrom RC, Rogers WO, et al. Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine 2001; 20(1-2): 275-80.
28. Bahloul C, Taieb D, Diouani MF, et al. Field trials of a very potent rabies DNA vaccine which induced long lasting virus neutralizing antibodies and protection in dogs in experimental conditions. Vaccine 2006; 24(8): 1063-72.
29. Omori-Urabe Y, Yoshii K, Ikawa-Yoshida A, Kariwa H, Takashima I. Needle free jet injection of DNA and protein vaccine of the Far Eastern subtype of tick borne encephalitis virus induces protective immunity in mice. Microbiol Immunol 2011; 55(12): 893-7.
30. Hooper JW, Ferro AM, Wahl-Jensen V. Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus. J Virol 2008; 82(3): 1332-8.
31. Lee BH, Yoshimatsu K, Araki K, Okumura M, Nakamura I, Arikawa J. A pseudotype vesicular stomatitis virus containing Hantaan virus envelope glycoproteins G1 and G2 as an alternative to hantavirus vaccine in mice. Vaccine 2006; 24(15): 2928-34.
32. Valdivieso F, Vial P, Ferres M, et al. Neutralizing antibodies in survivors of Sin Nombre and Andes hantavirus infection. Emerg Infect Dis 2006; 12(1): 166.
33. Ye C, Prescott J, Nofchissey R, Goade D, Hjelle B. Neutralizing antibodies and Sin Nombre virus RNA after recovery from hantavirus cardiopulmonary syndrome. Emerg Infect Dis 2004; 10(3): 478-82.